Immune System Deficiencies Do Not Alter SARS-CoV-2 Evolutionary Rate but Favour the Emergence of Mutations by Extending Viral Persistence
Authors:
- Laura ManutoLMLaura Manuto
- Martina BadoMBMartina Bado
- Marco ColaMCMarco Cola
- Elena VanzoEVElena Vanzo
- Maria AntonelloMAMaria Antonello
- Giorgia MazzottiGMGiorgia Mazzotti
- Monia PacentiMPMonia Pacenti
- Giampaolo CordioliGCGiampaolo Cordioli
- Lolita SassetLSLolita Sasset
- Anna Maria CattelanACAnna Maria Cattelan
- Stefano ToppoSTStefano Toppo
- Enrico LavezzoEnrico Lavezzo
Open Access
Abstract
During the COVID-19 pandemic, immunosuppressed patients showed prolonged SARS-CoV-2 infections, with several studies reporting the accumulation of mutations in the viral genome. The weakened immune system present in these individuals, along with the effect of antiviral therapies, are thought to create a favourable environment for intra-host viral evolution and have been linked to the emergence of new viral variants which strongly challenged containment measures and some therapeutic treatments. To assess whether impaired immunity could lead to the increased instability of viral genomes, longitudinal nasopharyngeal swabs were collected from eight immunocompromised patients and fourteen non-immunocompromised subjects, all undergoing SARS-CoV-2 infection. Intra-host viral evolution was compared between the two groups through deep sequencing, exploiting a probe-based enrichment method to minimise the possibility of artefactual mutations commonly generated in amplicon-based methods, which heavily rely on PCR amplification. Although, as expected, immunocompromised patients experienced significantly longer infections, the acquisition of novel intra-host viral mutations was similar between the two groups. Moreover, a thorough analysis of viral quasispecies showed that the variability of viral populations in the two groups is comparable not only at the consensus level, but also when considering low-frequency mutations. This study suggests that a compromised immune system alone does not affect SARS-CoV-2 within-host genomic variability.Keywords
Funding Information
- Università degli Studi di Padova (PRID/SID 2020, 2020XFNCP7)
- Italian Ministry of University and Research (PRIN 2020) (PRID/SID 2020, 2020XFNCP7)
This publication has 37 references indexed in Scilit:
- Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infectionCell Reports Medicine, 2022
- SARS-CoV-2 intra-host evolution during prolonged infection in an immunocompromised patientInternational Journal of Infectious Diseases, 2022
- De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case reportNature Communications, 2022
- Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing home of Southern ItalyInfection, Genetics and Evolution, 2022
- Genomic Perspectives on the Emerging SARS-CoV-2 Omicron VariantGenomics, Proteomics & Bioinformatics, 2022
- Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispeciesClinical Microbiology and Infection, 2021
- Transmissibility and viral replication of SARS‐COV‐2 in immunocompromised patientsJournal of Medical Virology, 2021
- Genomic monitoring of SARS-CoV-2 uncovers an Nsp1 deletion variant that modulates type I interferon responseCell Host & Microbe, 2021
- Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with CancerCell, 2020
- Nsp3 of coronaviruses: Structures and functions of a large multi-domain proteinAntiviral Research, 2018